For a population carrying a disproportionate Alzheimer's burden, identifying early, measurable warning signs before cognitive decline appears is one of medicine's most urgent priorities. New evidence suggests that a simple, non-invasive measure of arterial stiffness — derivable from routine blood pressure readings and age — may serve as a meaningful upstream signal of neurodegeneration in cognitively intact older African Americans, a group historically underrepresented in dementia research.

In a cross-sectional cohort of 145 cognitively unimpaired African American adults averaging 71 years of age, higher estimated pulse wave velocity (ePWV) — a validated proxy for arterial stiffness — correlated significantly with elevated plasma concentrations of phosphorylated tau217 (β=0.34), glial fibrillary acidic protein GFAP (β=0.55), and neurofilament light chain NfL (β=0.52), after adjusting for sex, education, hypertension status, waist-to-hip ratio, and global cognition. Notably, neither phosphorylated tau231 nor the amyloid-β42/40 ratio reached significance, suggesting the vascular-neurodegeneration pathway may operate somewhat independently of amyloid accumulation at this stage.

These findings sit at an important intersection of vascular and neurological aging research. The ePWV metric is compelling precisely because it requires no specialized imaging or lumbar puncture — it can be estimated from data already collected in primary care settings. That said, the cross-sectional design prevents any causal inference; we cannot determine whether stiffened arteries drive neurodegeneration or whether shared upstream factors, such as chronic inflammation or oxidative stress, produce both. The relatively small cohort of 145 participants also limits generalizability. Nevertheless, the biological plausibility is strong: reduced vascular compliance impairs cerebral perfusion and promotes blood-brain barrier disruption, both implicated in tau pathology and glial activation. For longevity-minded clinicians, this study adds weight to treating cardiovascular risk factors — hypertension in particular — not merely as heart disease prevention, but as an active strategy for preserving brain health decades before Alzheimer's symptoms emerge.